Hepatitis B remains a critical global health challenge, with over 290 million people living with chronic infection. As a Wholesale Hepatitis B Vaccine Inactivated Supplier, we understand that the demand for high-purity, recombinant HBsAg (Hepatitis B Surface Antigen) vaccines is not just a commercial transaction, but a vital component of the WHO's 2030 goal to eliminate viral hepatitis as a public health threat.
The "inactivated" terminology in the modern context primarily refers to the recombinant DNA process where the viral surface antigen is produced in yeast (Saccharomyces cerevisiae) or mammalian cells (CHO cells), purified, and then adsorbed onto adjuvants. This approach ensures zero risk of infection while maintaining high immunogenicity.
For bulk buyers and governmental health ministries, the vaccine supply chain involves more than just the vial. It requires a holistic macro-solution.
Utilizing IoT-enabled thermal monitoring and Phase Change Material (PCM) packaging to ensure zero-excursion delivery from manufacturing hub to the last mile.
Our partners strictly adhere to WHO Prequalification (PQ) standards and international GMP (Good Manufacturing Practice) to facilitate rapid local registration.
We provide solutions for localized manufacturing, including the supply of concentrated bulk antigens for local fill-finish facilities to reduce import duties.
Jiangxi Serum Pharma Industries Co., Ltd. is a professional supplier of pharmaceutical and nutritional products in China. For nearly 10 years, we have been dedicated to exporting biological products, vaccines, Western medicines, and medical consumables.
Founded with a vision for global pharmaceutical accessibility.
Proven track record in high-value vaccine and API export.
Early technology using HBsAg from human plasma (Now largely obsolete).
Yeast/CHO cell-based antigens. Highly safe, standard of care worldwide.
Incorporating Pre-S1 and Pre-S2 for faster seroconversion in non-responders.
Next-gen adjuvants and mRNA delivery for therapeutic hepatitis vaccines.
The Hepatitis B Vaccine Inactivated (Recombinant HBsAg) is synthesized through a sophisticated biopharmaceutical process. Unlike live-attenuated vaccines, the inactivated recombinant antigen poses no risk of revertant virulence, making it safe for immunocompromised individuals and infants. The purity levels of the antigen must exceed 99% to minimize adverse reactions, a standard we ensure through multi-stage chromatography and ultrafiltration.
One of the critical components in vaccine efficacy is the adjuvant system. Most traditional formulations use Alum (Aluminum Hydroxide), which triggers a strong Th2 immune response. However, modern industrial trends are moving towards CpG ODN and other TLR9 agonists to enhance Th1 responses, particularly for older adults or dialysis patients who typically show poor response to standard vaccines.
From a procurement perspective, the stability of the vaccine at various temperatures—often referred to as the Controlled Temperature Chain (CTC)—is becoming a vital research area. Being able to keep vaccines outside the cold chain for several days during birth dose campaigns in remote areas can increase immunization coverage by up to 30%.
As a leading supplier, we also focus on the combination vaccine market. The Hexavalent vaccine (DTaP-Hib-IPV-HepB) is rapidly replacing monovalent doses in private sectors and advanced healthcare systems, simplifying immunization schedules and reducing needle-stick injuries.
Navigating the Ministry of Health (MoH) requirements in different countries can be daunting. We provide a full CTD (Common Technical Document) dossier for our biological products, including:
We offer diverse presentation formats to suit local market needs:
1. Single-dose Prefilled Syringes (PFS): Minimizes waste and contamination risk.
2. Multi-dose Vials (10-dose): Cost-effective for mass vaccination campaigns.
3. Low-dead-space Syringe compatibility.
